NPPA and obstructive sleep apnea syndrome: Additionally, within the OSA patient group, our results indicated that there was no difference in the levels of proADM [0.62 (0.54–0.73) vs 0.62 (0.55–0.76), p = 0.503], proANP [55.76 (40.00–83.78) vs 54.81 (43.21–90.91), p = 0.998] and copeptin [8.12 (5.30–11.18) vs 7.17 (4.73–10.46), p = 0.207] among patients with and without OSAS, respectively.